Gadolinium contrast media during pregnancy and lactation

Acta Radiologica

Volumn 54, Issue 6, 2013, Pages 599-600

  Webb, Judith A W ^a   Thomsen, Henrik S ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ANIMAL; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC IMAGING; DRUG EFFECT; EDITORIAL; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; LACTATION; NEPHROGENIC SYSTEMIC FIBROSIS; OFF LABEL DRUG USE; PREGNANCY; PRENATAL EXPOSURE;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; FEMALE; GADOLINIUM; HUMANS; LACTATION; MATERNAL-FETAL EXCHANGE; NEPHROGENIC FIBROSING DERMOPATHY; OFF-LABEL USE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84886607051     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185113484894     Document Type: Editorial

References (22)

1. Webb JAW, Thomsen HS, Morcos SK, et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005;15:1234-40.
2. Muhler MR, Clement O, Salomon LJ, et al. Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology 2011;258:455-60.
3. Okazaki O, Murayama N, Masubuchi N, et al. Placental transfer and milk secretion of gadodiamide injection in rats. Arzneimittelforschung/Drug Res 1996;46:83-6.
4. Beall MH, Ross MG. Amniotic Fluid Dynamics. In: Creasy RK, Resnik R, Iams JD, et al., eds. Maternal-Foetal Medicine: Principles and Practice. 6th edn. London: Saunders Elsevier 2009:48-9.
5. Barkhof E, Heijboer RJJ, Algra PR. Inadvertent iv administration of gadopentetate dimeglumine during early pregnancy. Am J Roentgenol 1992;158:1171.
6. Shoenut JP, Semelka RC, Silverman R, et al. MRI in the diagnosis of Crohn's disease in two pregnant women. J Clin Gastroenterol 1993;17:244-7.
7. Marcos HB, Semelka RC, Worowattankul S. Normal placenta: gadolinium enhanced dynamic MR imaging. Radiology 1997;205:493-6.
8. Spencer JA, Tomlinson AJ, Weston MJ, et al. Early report: comparison of breath-hold MR excretory urography, Doppler ultrasound and isotope renography in evaluation of symptomatic hydronephrosis in pregnancy. Clin Radiol 2000;55:446-53.
9. Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute pelvic and abdominal pain in pregnant patients. Am J Roentgenol 2005;184:452-8.
10. De Santis M, Straface G, Cavaliere AF, et al. Gadolinium periconceptual exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol 2007;86:99-101.
11. Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology 2000;216:555-8.
12. Marti-Bonmati L, Vega T, Benito C, et al. Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase 111 open multicenter study. Invest Radiol 2000;35:141-7.
13. Tsai-Goodman B, Geva T, Odegard KC, et al. Clinical role, accuracy and technical aspects of cardiovascular magnetic resonance imaging in infants. Am J Cardiol 2004;94:69-74.
14. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. Am J Roentgenol 1984;142:619-24.
15. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabelled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-80.
16. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73.
17. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-8.
18. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:271-80.
19. K-DOQI Clinical Practice Guidelines Part 4. Definitions and classification of stages of chronic kidney disease. Am J Kidney Dis 2002;39 (Suppl. 1):S46-75.
20. COMMISSION DECISION of 1.7.2010 concerning, in the framework of Article 31 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for Gadolinium-containing contrast agents for human use which contain one or more of the active substances "gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid". See http://ec.europa.eu/health/documents/community- register/html/refh-others.htm.
21. ESUR guidelines on Contrast Media version 8.0. See http://www.esur.org/ guidelines/.
22. Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium based contrast media: updated ESUR Contrast Medium Safety Committee Guidelines. Eur Radiol 2013;23:307-18.